文献速递术前评估与围术期医学疼痛医学

右美托咪定无阿片平衡麻醉与瑞芬太尼平衡麻醉在大中型非心脏手术中的比较

Balanced Opioid-free Anesthesia with Dexmedetomidine versus Balanced Anesthesia with Remifentanil for Major or Intermediate Noncardiac Surgery.
PubMed 文献 · Anesthesiology · 2021-01-01

主要复合终点(术后48小时内阿片相关不良事件)在右美托咪定组发生率为78%,高于瑞芬太尼组的67%(RR 1.16,95%CI 1.01-1.33,P=0.031),低氧血症发生率也更高(72% vs 61%,RR 1.19,95%CI 1.02-1.40,P=0.030)。右美托咪定组术后48小时累计吗啡消耗量和术后恶心呕吐更少,但拔管延迟和PACU停留时间延长。

要点

  • 右美托咪定无阿片麻醉未减少术后阿片相关不良事件,反而增加低氧血症和严重心动过缓风险。
  • 右美托咪定组术后48小时累计吗啡消耗量和恶心呕吐发生率更低,但镇痛效果相似。
  • 右美托咪定组拔管延迟和PACU停留时间延长,需警惕心动过缓等严重不良事件。

核心结论

  • 该试验否定了右美托咪定无阿片平衡麻醉相比瑞芬太尼减少术后阿片相关不良事件的假设,反而发现严重不良事件(尤其是低氧血症和心动过缓)发生率更高。

研究设计与样本

  • 随机对照试验,纳入大中型非心脏手术患者,随机接受右美托咪定无阿片平衡麻醉或瑞芬太尼平衡麻醉,因右美托咪定组5例严重心动过缓提前终止。

主要发现

  • 主要复合终点(术后48小时内低氧血症、肠麻痹或认知功能障碍)在右美托咪定组156例中122例(78%)发生,瑞芬太尼组156例中105例(67%)发生(RR 1.16,95%CI 1.01-1.33,P=0.031)。
  • 低氧血症在右美托咪定组152例中110例(72%)发生,瑞芬太尼组155例中94例(61%)发生(RR 1.19,95%CI 1.02-1.40,P=0.030)。
  • 肠麻痹和认知功能障碍两组无差异。
  • 术后0-48小时累计吗啡消耗量右美托咪定组为11 mg(5-21),瑞芬太尼组为6 mg(0-17);术后恶心呕吐右美托咪定组157例中58例(37%),瑞芬太尼组157例中37例(24%)(RR 0.64,95%CI 0.45-0.90)。
  • 两组镇痛措施相似,但右美托咪定组拔管延迟和PACU停留时间延长。

临床怎么用

  • 在大中型非心脏手术中,采用右美托咪定无阿片平衡麻醉需权衡其增加的低氧血症和心动过缓风险,并注意拔管延迟和PACU停留时间延长。

局限性

  • 研究因右美托咪定组严重心动过缓而提前终止,可能影响统计效能和结果解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is speculated that opioid-free anesthesia may provide adequate pain control while reducing postoperative opioid consumption. However, there is currently no evidence to support the speculation. The authors hypothesized that opioid-free balanced anesthetic with dexmedetomidine reduces postoperative opioid-related adverse events compared with balanced anesthetic with remifentanil. METHODS: Patients were randomized to receive a standard balanced anesthetic with either intraoperative remifentanil plus morphine (remifentanil group) or dexmedetomidine (opioid-free group). All patients received intraoperative propofol, desflurane, dexamethasone, lidocaine infusion, ketamine infusion, neuromuscular blockade, and postoperative lidocaine infusion, paracetamol, nefopam, and patient-controlled morphine. The primary outcome was a composite of postoperative opioid-related adverse events (hypoxemia, ileus, or cognitive dysfunction) within the first 48 h after extubation. The main secondary outcomes were episodes of postoperative pain, opioid consumption, and postoperative nausea and vomiting. RESULTS: The study was stopped prematurely because of five cases of severe bradycardia in the dexmedetomidine group. The primary composite outcome occurred in 122 of 156 (78%) dexmedetomidine group patients compared with 105 of 156 (67%) in the remifentanil group (relative risk, 1.16; 95% CI, 1.01 to 1.33; P = 0.031). Hypoxemia occurred 110 of 152 (72%) of dexmedetomidine group and 94 of 155 (61%) of remifentanil group patients (relative risk, 1.19; 95% CI, 1.02 to 1.40; P = 0.030). There were no differences in ileus or cognitive dysfunction. Cumulative 0 to 48 h postoperative morphine consumption (11 mg [5 to 21] versus 6 mg [0 to 17]) and postoperative nausea and vomiting (58 of 157 [37%] versus 37 of 157 [24%]; relative risk, 0.64; 95% CI, 0.45 to 0.90) were both less in the dexmedetomidine group, whereas measures of analgesia were similar in both groups. Dexmedetomidine patients had more delayed extubation and prolonged postanesthesia care unit stay. CONCLUSIONS: This trial refuted the hypothesis that balanced opioid-free anesthesia with dexmedetomidine, compared with remifentanil, would result in fewer postoperative opioid-related adverse events. Conversely, it did result in a greater incidence of serious adverse events, especially hypoxemia and bradycardia.

来源:Anesthesiology,查看原文。版权归原作者所有。

引用

  1. Beloeil H, Garot M, Lebuffe G, et al. Balanced Opioid-free Anesthesia with Dexmedetomidine versus Balanced Anesthesia with Remifentanil for Major or Intermediate Noncardiac Surgery. Anesthesiology. 2021. PMID: 33630043. doi:10.1097/ALN.0000000000003725

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。